BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ARCA Discovery Inc. Names Thomas Keuer Executive Vice President Of Pharmaceutical Operations


10/31/2006 10:34:10 AM

DENVER, Oct. 30 /PRNewswire/ -- ARCA Discovery, Inc., a privately held biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases, today announced the appointment of Thomas A. Keuer, as Executive Vice President of Pharmaceutical Operations. Mr. Keuer has over twenty five years of experience in the biotechnology and pharmaceutical industries at Insmed Inc., Baxter International, Somatogen, and Monsanto. Most recently, he served as Senior Vice President, Insmed Therapeutic Proteins with responsibility for all aspects of the Therapeutic Protein Manufacturing Program and Boulder site. Prior to that, he held the position of Vice President of Engineering for the Biosciences Division of Baxter International. Mr. Keuer received his Masters of Science in Biochemical Engineering from Rice University as a Monsanto-sponsored delegate.

In making the announcement, ARCA's President and Chief Executive Officer Dr. Michael R. Bristow said, "We are very pleased to have Tom Keuer join the ARCA team. He brings to the Company the operational expertise, experienced leadership and knowledge in Chemistry, Manufacturing & Controls that we need to meet the regulatory challenges of drug development, and prepare for commercialization of our lead product, bucindolol."

"I believe that ARCA's approach for development of targeted, optimized therapies for cardiovascular disease will represent a major advancement in personalized medicine. I look forward to working with the ARCA team to commercialize bucindolol and provide this important therapy to the patients who need it," said Mr. Keuer.

About ARCA Discovery, Inc.

ARCA Discovery, Inc. is a privately held biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases. The Company's first product is bucindolol, a third generation beta-blocker-vasodilator for advanced heart failure and other indications, that promises to be the first genetically-targeted cardiovascular drug. Bucindolol has extensive Phase III data and a unique Phase III DNA sub-study. Using this sub-study, ARCA's founding scientists have confirmed two genetic polymorphisms that interact with bucindolol's unique pharmacology to modify patient response. ARCA is preparing an NDA for bucindolol and intends to seek FDA approval of bucindolol during 2007.

ARCA Discovery, Inc.

CONTACT: Michael Bristow MD, PhD, President and Chief Executive Officer ofARCA Discovery, Inc., +1-303-893-1599



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES